Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab
This study is ongoing, but not recruiting participants.
Sponsor:
Mayo Clinic
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01393821
First received: June 27, 2011
Last updated: May 1, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab
| Condition | Intervention |
|---|---|
|
Dermatologic Complications Malignant Neoplasm Pain |
Drug: menadione topical lotion Other: placebo Other: questionnaire administration Procedure: management of therapy complications |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress |
Resource links provided by NLM:
Further study details as provided by Mayo Clinic:
Primary Outcome Measures:
- Cutaneous discomfort as measured by the face pain scale question. Descriptive statistics and longitudinal plots will be used for summarizing cutaneous discomfort. [ Time Frame: Weekly during the 4-week treatment period ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Adverse event profile of a topical menadione-containing lotion [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
- Long-term cutaneous and psychosocial discomfort and adverse event [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2012 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I (lotion)
Patients apply menadione topical lotion BID for 28 days.
|
Drug: menadione topical lotion
Given topically
Other: questionnaire administration
Ancillary studies
Procedure: management of therapy complications
Given menadione topical lotion
Other Name: complications of therapy, management of
|
|
Placebo Comparator: Arm II (placebo)
Patients apply topical placebo lotion BID for 28 days.
|
Other: placebo
Given topically
Other Name: PLCB
Other: questionnaire administration
Ancillary studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. Explore the effectiveness of a menadione topical lotion to the face to prevent cutaneous and psychological discomfort from epidermal growth factor receptor (EGFR) inhibitors.
SECONDARY OBJECTIVES:
I. Explore the adverse event profile of a menadione topical lotion to the face to prevent rash from EGFR inhibitors.
II. Explore whether rash or adverse events worsen over a 4 week period after this 4-week intervention.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients apply menadione topical lotion twice daily (BID) for 28 days.
ARM II: Patients apply topical placebo lotion BID for 28 days.
After completion of study treatment, patients are followed up for 4 weeks.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18 years or older.
- Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity.
- Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.
- Ability to complete questionnaire(s) by themselves or with assistance.
- Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for women of childbearing potential only.
- Willing to have photographs taken to assess rash.
Exclusion Criteria:
- Any active facial and/or chest rash, including adult acne, at the time of randomization.
- Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest.
- Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks.
- Any type of ongoing therapy for rash.
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects
- Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following study enrollment.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01393821
Locations
| United States, Arizona | |
| Mayo Clinic Campus in Arizona | |
| Scottsdale, Arizona, United States | |
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States, 55905 | |
Sponsors and Collaborators
Mayo Clinic
Investigators
| Study Chair: | Aminah Jatoi, M.D. | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Jatoi, Aminah, Mayo Clinic Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01393821 History of Changes |
| Other Study ID Numbers: | MC10C9, NCI-2011-01047 |
| Study First Received: | June 27, 2011 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Neoplasms Vitamin K 3 Vitamin K Erlotinib Vitamins Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions |
Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants Hematologic Agents Therapeutic Uses Protein Kinase Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on June 17, 2013